<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02269475</url>
  </required_header>
  <id_info>
    <org_study_id>D2560C00006</org_study_id>
    <nct_id>NCT02269475</nct_id>
  </id_info>
  <brief_title>A Phase3 Study to Evaluate the Efficacy and Safety of MEDI3250 in Healthy Japanese Children Age 7 Years Through 18 Years</brief_title>
  <official_title>A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of MEDI3250 Compared to Placebo in Healthy Japanese Children Age 7 Years Through 18 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to gather the efficacy, safety and tolerability data in Japanese
      children 7 to 18 years of age that would support approval of MEDI3250 in Japan.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized, double-blind, placebo controlled, multicenter study will enrol 1008
      subjects. The study is designed to gather the efficacy, safety and tolerability data in
      Japanese children 7 through 18 years of age that would support approval of MEDI3250 in Japan.

      For children age 7 years through 18 years, the recommended dosage schedule for intranasal
      administration is 0.2 mL (0.1 mL per nostril). For children age 7 years through 8 years not
      previously vaccinated against seasonal influenza, a second dose should be given after an
      interval of at least 4 weeks.

      For the efficacy endpoint, data will be gathered on the incidence of laboratory-confirmed
      influenza-like illness in the two treatment arms. Laboratory-confirmed influenza-like illness
      would include cases of influenza diagnosed using culture-confirmation and/or PCR-based
      methods.

      For the safety and tolerability endpoint, data will be gathered on solicited symptoms, AEs
      and SAEs.

      Subject will be randomized 2:1 to receive MEDI3250 or placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the Incidence of Laboratory-confirmed Influenza Infection (Matched Strain)</measure>
    <time_frame>through the end of the influenza surveillance period, up to end Apr (6 months)</time_frame>
    <description>The vaccine efficacy of MEDI3250 compared to placebo against the incidence of laboratory-confirmed influenza infection (matched strain)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the Incidence of Laboratory-confirmed Influenza Infection (Any Strain)</measure>
    <time_frame>through the end of the influenza surveillance period, up to end Apr (6 months)</time_frame>
    <description>The vaccine efficacy of MEDI3250 compared to placebo against the incidence of laboratory-confirmed influenza infection (any strain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the Incidence of Laboratory-confirmed Influenza Infection (Matched Strain, by Strain)</measure>
    <time_frame>through the end of the influenza surveillance period, up to end Apr (6 months)</time_frame>
    <description>The vaccine efficacy of MEDI3250 compared to placebo against the incidence of laboratory-confirmed influenza infection (matched strain, by strain)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1369</enrollment>
  <condition>Healthy Japanese Children Age 7 Years Through 18 Years</condition>
  <arm_group>
    <arm_group_label>MEDI3250</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI3250 Nasal Spray</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Nasal spray</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI3250</intervention_name>
    <description>MEDI3250</description>
    <arm_group_label>MEDI3250</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 7 through 18 years of age at the time of randomization.

          2. A written informed consent should be obtained from the subject's legally acceptable
             representative, and a written informed assent should be obtained from the subject if
             possible.

          3. Available for illness visits at clinic during the influenza surveillance period.

          4. Ability of the legal representative to understand and comply with the requirements of
             the protocol．

          5. Parent/guardian available by telephone, email or etc．

          6. Females of childbearing potential, unless surgically sterile (ie, bilateral tubal
             ligation, bilateral oophorectomy, or hysterectomy), has sterile male partner, is
             premenarchal, or practices abstinence, must have used an effective method of avoiding
             pregnancy (including oral, transdermal, or implanted contraceptives, intrauterine
             device, female condom with spermicide, diaphragm with spermicide, cervical cap with
             spermicide, or use of a condom with spermicide by the sexual partner) for 30 days
             prior to the first dose of investigational product, and must agree to continue using
             such precautions for 60 days after the final dose of investigational product.

          7. A subject who is considered by the investigator to be at risk of pregnancy must also
             have a negative urine pregnancy test at screening and, if screening and Day 0 do not
             occur on the same day, on the day of vaccination prior to randomization. Investigator
             judgment is required to assess each subject's need for pregnancy testing.

          8. Healthy by medical history and physical examination OR presence of stable underlying
             chronic medical condition for which hospitalization has not been required in the
             previous year.

        Exclusion Criteria:

          1. Subjects who were previously administered influenza vaccine in 2014-2015 influenza
             season

          2. Previous randomisation in the present study

          3. Participation in another clinical study with an investigational product during the
             last 3 month

          4. Acute illness or evidence of significant active infection at randomization;

          5. Fever ≥99.5°F (37.5°C) at randomization;

          6. Any drug therapy from 15 days prior to randomization or expected drug therapy through
             28 days post last dose with the exception of the following classes/types of
             medications, which are allowed:

             Contraceptives (change in contraceptive type or method is acceptable as long as
             guidelines are followed for prevention of pregnancy during change); Topical
             corticosteroids, calcineurin inhibitors, or antifungals for uncomplicated dermatitis;
             Chronic medications (including those taken on an as-needed basis) that have been well
             tolerated and were not initiated and/or did not have a dosage change within 90 days
             prior to randomization.

          7. Current or expected receipt of immunosuppressive medications within a 28-day window
             around any dose, including an immunosuppressive dose of corticosteroids, which is
             defined as ≥20 mg/day of prednisone or its equivalent, given daily or on alternate
             days for ≥15 days (intranasal, intra-articular, and topical corticosteroids are
             permitted); Note: topical corticosteroids for uncomplicated dermatitis may be used
             throughout the study according to the judgment of the investigator; topical
             calcineurin inhibitors may be used in accordance with their package insert at entry
             and during study participation.

          8. Any known immunosuppressive condition or immune deficiency disease including known or
             suspected infection with human immunodeficiency virus (HIV);

          9. History of allergic disease or reactions likely to be exacerbated by any component of
             the investigational product including allergy to eggs, egg proteins, gentamicin, or
             gelatin or serious, life threatening, or severe reactions to previous influenza
             vaccinations;

         10. Use of aspirin or salicylate-containing medications within 28 days prior to
             randomization or expected receipt through the entire study;

         11. History of Guillain-Barré syndrome;

         12. Use of antiviral agents with activity against influenza virus (including amantadine,
             rimantadine, oseltamivir, and zanamivir) within 28 days prior to first dose of
             investigational product or anticipated use of such agents in the study period;

         13. Administration of any live virus vaccine within 30 days prior to enrolment, or if
             receipt of another live virus vaccine is expected within 30 days of any study
             vaccination;

         14. Administration of any inactivated vaccine within 14 days prior to enrolment or if
             receipt of another inactivated vaccine is expected within 14 days of any study
             vaccination;

         15. Receipt of any blood product within 90 days prior to vaccination or expected receipt
             during this study;

         16. Pregnant or lactating female

         17. Involvement in the planning and conduct of the study (applies to all AstraZeneca staff
             and staff at the study site as a legal representative)

         18. Any condition that, in the opinion of the investigator, might interfere with the
             interpretation or evaluation of the vaccines.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masaki Yokohama, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yokohama clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Toshiko Yamaguchi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yamaguchi Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Haruo Maeta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maeta Pediatrics Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hideki Nakazawa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HIGASHIKATSUYAMA nakazawa Naika allergy Internal Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Atsushi Shibasaki, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shibasaki internal medicine &amp; Pediatrics Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yutaka Igarashi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Igarashi Children's Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Keiko Mitamura, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eiju General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Satoshi Yamada, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyouai Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kiyoshi Niwa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Niwa Family Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ryuta Ono, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kanagawa HImawari Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eiji Kato, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fukuiken Saiseikai Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Toshikazu Takahashi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Takahashi Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ryouta Yoshimura, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yoshimura Children's Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hiroshi Taniguchi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taniguchi Pediatrics Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hidehisa Shinohara, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shinohara Pediatrics Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michiko Tanabe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tanabe Pediatrics Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Haruo Kuroki, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sotobo Children's Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hirokazu Sato, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunrise Children's Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Katsumi Yamada, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yamada Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hiroshi Sakiyama, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sakiyama Pediatric Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hiroji Okawa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Okawa Children &amp; Family Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Junichi Ito, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ito ENT Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Masato Morimoto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MORIMOTO ENT CLINIC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Masakazu Umemoto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Umemoto Pediatric Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tadashi Matuda, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Matsuda Pediatrics Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sadayoshi Torigoe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aquair Medical Station</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shigeru Mori, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Momotaro Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yutaka Fujimaki, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fujimaki Ent Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Masaki Kato, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kato Ear Nose Throat Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hisakuni Sekino, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sekino Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Toshikazu Nagakura, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yoga Allergy Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ichiro Ogiwara, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ogiwara Ent Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Akitoshi Funato, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical corporation Seisyuukai Funato Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Naohisa Hoshino, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical corporation Ryoshukai Kanauchi Medical Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Munechika Noguchi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Social medical corporation IHL ShinagawaEastOne Medical Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chiaki Noguchi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shinkoiwa Ekimae Sougou Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kimihiko Yukisada, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yukisada Clinic for internal disease</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hiroshi Shimomura, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical corporation Junyokai Musashino General Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mitsuhiro Nemoto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nemoto-geka-seikeigeka</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Naoki Kawai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kawai Naika Iin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shigehiro Yazima, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yajima Children's Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tetsuhiko Nagao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Midorino Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kenjiro Nakamura, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tenjin Sogo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wataru Ikematsu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kobori Building Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shiro Kimura, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kimura Shiro Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mieko Ueda, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ueda Naika Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Minako Iwaya, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Iwaya Children's Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Motohisa Ikeda, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ikeda Naika Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tetsunari Maeda, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sakura Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Akashi-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chofu-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fuchu-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fujimi-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukui-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukuoka-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukuroi-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Funabashi-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gifu-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hatsukaichi-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hiroshima-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ichikawa-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Isumi-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iwate-gun</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Katsushika-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kawasaki-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kisarazu-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kiyose-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kobe-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Koga-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kumamoto-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kunitachi-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kuwana-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Matsudo-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Minato-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Morioka-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nakano-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Okayama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ota-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sapporo-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sendai-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Setagaya-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shinjuku-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shizuoka-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taito-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toshima-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tsu-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yokkaichi-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2014</study_first_submitted>
  <study_first_submitted_qc>October 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2014</study_first_posted>
  <results_first_submitted>October 29, 2015</results_first_submitted>
  <results_first_submitted_qc>October 29, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 3, 2015</results_first_posted>
  <last_update_submitted>March 6, 2017</last_update_submitted>
  <last_update_submitted_qc>March 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Efficacy</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>MEDI3250</keyword>
  <keyword>Japanese children</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Of the 1369 consented, 68 were excluded after screening.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>MEDI3250</title>
          <description>MEDI3250, 0.2mL as nasal spray</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo, 0.2mL as nasal spray</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="868"/>
                <participants group_id="P2" count="433"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received IP (Safety Population)</title>
              <participants_list>
                <participants group_id="P1" count="868"/>
                <participants group_id="P2" count="433"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Per Protocol Population</title>
              <participants_list>
                <participants group_id="P1" count="849"/>
                <participants group_id="P2" count="430"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="865"/>
                <participants group_id="P2" count="432"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Meet Exclusion Criteria No. 17</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MEDI3250</title>
          <description>MEDI3250, 0.2mL as nasal spray</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo, 0.2mL as nasal spray</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="868"/>
            <count group_id="B2" value="433"/>
            <count group_id="B3" value="1301"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.0" spread="3.0"/>
                    <measurement group_id="B2" value="10.8" spread="2.8"/>
                    <measurement group_id="B3" value="10.9" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="408"/>
                    <measurement group_id="B2" value="226"/>
                    <measurement group_id="B3" value="634"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="460"/>
                    <measurement group_id="B2" value="207"/>
                    <measurement group_id="B3" value="667"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Doses of Study Vaccine to be Received</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="841"/>
                    <measurement group_id="B2" value="421"/>
                    <measurement group_id="B3" value="1262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Influenza Vaccination</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="788"/>
                    <measurement group_id="B2" value="386"/>
                    <measurement group_id="B3" value="1174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>the Incidence of Laboratory-confirmed Influenza Infection (Matched Strain)</title>
        <description>The vaccine efficacy of MEDI3250 compared to placebo against the incidence of laboratory-confirmed influenza infection (matched strain)</description>
        <time_frame>through the end of the influenza surveillance period, up to end Apr (6 months)</time_frame>
        <population>Per Protocol Population</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI3250</title>
            <description>MEDI3250, 0.2mL as nasal spray</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, 0.2mL as nasal spray</description>
          </group>
        </group_list>
        <measure>
          <title>the Incidence of Laboratory-confirmed Influenza Infection (Matched Strain)</title>
          <description>The vaccine efficacy of MEDI3250 compared to placebo against the incidence of laboratory-confirmed influenza infection (matched strain)</description>
          <population>Per Protocol Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="849"/>
                <count group_id="O2" value="430"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Vaccine efficacy (%)</param_type>
            <param_value>100.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1875.3</ci_lower_limit>
            <ci_upper_limit>100.0</ci_upper_limit>
            <estimate_desc>Vaccine efficacy (%) = (1-RR)*100 where RR = Risk Reduction.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>the Incidence of Laboratory-confirmed Influenza Infection (Any Strain)</title>
        <description>The vaccine efficacy of MEDI3250 compared to placebo against the incidence of laboratory-confirmed influenza infection (any strain)</description>
        <time_frame>through the end of the influenza surveillance period, up to end Apr (6 months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MEDI3250</title>
            <description>MEDI3250, 0.2mL as nasal spray</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, 0.2mL as nasal spray</description>
          </group>
        </group_list>
        <measure>
          <title>the Incidence of Laboratory-confirmed Influenza Infection (Any Strain)</title>
          <description>The vaccine efficacy of MEDI3250 compared to placebo against the incidence of laboratory-confirmed influenza infection (any strain)</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="849"/>
                <count group_id="O2" value="430"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169"/>
                    <measurement group_id="O2" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Vaccine efficacy (%)</param_type>
            <param_value>27.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.4</ci_lower_limit>
            <ci_upper_limit>43.0</ci_upper_limit>
            <estimate_desc>Vaccine efficacy (%) = (1-RR)*100 where RR = Risk Reduction.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>the Incidence of Laboratory-confirmed Influenza Infection (Matched Strain, by Strain)</title>
        <description>The vaccine efficacy of MEDI3250 compared to placebo against the incidence of laboratory-confirmed influenza infection (matched strain, by strain)</description>
        <time_frame>through the end of the influenza surveillance period, up to end Apr (6 months)</time_frame>
        <population>Per Protocol Population</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI3250</title>
            <description>MEDI3250, 0.2mL as nasal spray</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, 0.2mL as nasal spray</description>
          </group>
        </group_list>
        <measure>
          <title>the Incidence of Laboratory-confirmed Influenza Infection (Matched Strain, by Strain)</title>
          <description>The vaccine efficacy of MEDI3250 compared to placebo against the incidence of laboratory-confirmed influenza infection (matched strain, by strain)</description>
          <population>Per Protocol Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="849"/>
                <count group_id="O2" value="430"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strain A_H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain A_H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain B_Yamagata</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain B_Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs experienced from administration of investigational product through 28 days post last vaccination were collected</time_frame>
      <group_list>
        <group group_id="E1">
          <title>MEDI3250</title>
          <description>MEDI3250, 0.2mL as nasal spray</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo, 0.2mL as nasal spray</description>
        </group>
        <group group_id="E3">
          <title>Total Number</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="1301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1301"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1301"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1301"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0.01</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="126" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="193" subjects_at_risk="1301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="868"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="433"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="1301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>nasopharyngitis</sub_title>
                <counts group_id="E1" events="70" subjects_affected="70" subjects_at_risk="868"/>
                <counts group_id="E2" events="36" subjects_affected="36" subjects_at_risk="433"/>
                <counts group_id="E3" events="106" subjects_affected="106" subjects_at_risk="1301"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="868"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="433"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="1301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>rhinorrhoea</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="868"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="433"/>
                <counts group_id="E3" events="23" subjects_affected="23" subjects_at_risk="1301"/>
              </event>
              <event>
                <sub_title>upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="868"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="433"/>
                <counts group_id="E3" events="26" subjects_affected="26" subjects_at_risk="1301"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="868"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="433"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="1301"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Hideo Negi</name_or_title>
      <organization>CO RIA TA, R&amp;D</organization>
      <phone>+81 6 4803 3533 ext 4716</phone>
      <email>H.Negi@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

